Search research articles
Contact Us
Filters
Showing results (111-120 of 187) with videos related to
Page
of 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer
Stephen V Liu, D Ross Camidge, Scott N Gettinger, et al.
Therapeutic Advances in Medical Oncology
|
November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON study
Ferdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
The Lancet. Oncology
|
February 4, 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Giuseppe Giaccone, Chul Kim, Jillian Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2019
Detection of NRG1 Gene Fusions in Solid Tumors
Sushma Jonna, Rebecca A Feldman, Jeffrey Swensen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 27, 2011
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial
Barbara J Gitlitz, Denice D Tsao-Wei, Susan Groshen, et al.
Expert Review of Anticancer Therapy
|
April 16, 2025
Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)
Luis E Raez, Yasmine Baca, Jennifer R Ribeiro, et al.
Cancer Immunology, Immunotherapy : CII
|
May 11, 2026
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy
Milan Radovich, James Wacker, Jeffrey Solzak, et al.
BMJ Oncology
|
January 31, 2025
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma
Khalil Choucair, Andrew Elliott, Matthew James Oberley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2025
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials
David E Gerber, Claire R Wynters, Tanushree Prasad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2026
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
Ryan A McMahon, Kevin Lee Min Chua, Corinne Faivre-Finn, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 187) with videos related to
Sort By:
Page
of 19
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer
Stephen V Liu, D Ross Camidge, Scott N Gettinger, et al.
Therapeutic Advances in Medical Oncology
|
November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON study
Ferdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
The Lancet. Oncology
|
February 4, 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Giuseppe Giaccone, Chul Kim, Jillian Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2019
Detection of NRG1 Gene Fusions in Solid Tumors
Sushma Jonna, Rebecca A Feldman, Jeffrey Swensen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 27, 2011
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial
Barbara J Gitlitz, Denice D Tsao-Wei, Susan Groshen, et al.
Expert Review of Anticancer Therapy
|
April 16, 2025
Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)
Luis E Raez, Yasmine Baca, Jennifer R Ribeiro, et al.
Cancer Immunology, Immunotherapy : CII
|
May 11, 2026
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy
Milan Radovich, James Wacker, Jeffrey Solzak, et al.
BMJ Oncology
|
January 31, 2025
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma
Khalil Choucair, Andrew Elliott, Matthew James Oberley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2025
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials
David E Gerber, Claire R Wynters, Tanushree Prasad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2026
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
Ryan A McMahon, Kevin Lee Min Chua, Corinne Faivre-Finn, et al.
Page
of 19